SUNPHARMA.NS

Sun Pharmaceutical Industries

Health Care · Pharmaceuticals · NSE

$1,788.80

Data: 2026-05-09

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$4.4T

Total market value of the company

Trailing P/E

40.65

Expensive — high growth expected

Forward P/E

32.66

Based on estimated future earnings — lower means cheaper

Rev Growth

+13.5%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

N/A

Consensus view from ? analysts covering this stock

About Sun Pharmaceutical Industries

Company description not available.

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

2.6% PASS

Debt must be below 33% of total assets

Cash Ratio

11.2% PASS

Interest-bearing cash below 33% of assets

Receivables

14.2% PASS

Receivables below 49% of assets

Revenue Purity

1.9% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$772.31

What our model estimates this business is worth per share

Margin of Safety

-131.6%

Trading above fair value — no margin of safety

Rating

AVOID

Overall assessment combining ethics, valuation, and quality

Percentile

85.6th

Ranks in the top 14% of our 13,571 screened universe

Ethical Score

86.5

Valuation Score

30.5

Quality Score

40.0

Combined

57.3

Trading at $1848, 139% above fair value of $772. Passes all ethical screens. Ranks better than 48% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.720

Good returns relative to risk taken

Kelly Fraction

0.0559

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.696

Acceptable balance between returns and drawdown risk

Annual Return

13.3%

Historical annualised return based on price data

Max Drawdown

-19.1%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$N/A

52W Low

$N/A

Avg Volume

N/A

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

0.9%

Annual dividend as a percentage of the share price

EPS (TTM)

$45.46

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

6.68

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

N/A

Loss-making — spending exceeds revenue after all costs

Recent Insider Activity

SEC Form 4 filings — what company insiders are buying and selling

Date	Insider	Title	Type	Shares	Value
2026-01-13	Life Insurance Corporation of India	Institution- Corporation		202,500	—

Source: SEC Form 4 filings via public data. View all insider activity at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-09

Before you go